Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00963937
First received: August 20, 2009
Last updated: July 28, 2011
Last verified: July 2011
  Purpose

The purpose of this study is to evaluate the efficacy and safety of a range of doses of oral sumatriptan for the acute treatment of migraine in children ages 10 to 17.


Condition Intervention Phase
Migraine Disorders
Migraine
Drug: Sumatriptan 25 mg
Drug: Sumatriptan 50 mg
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Percentage of Participants Who Reported Pain Relief at 120 Minutes Post-Treatment [ Time Frame: 120 minutes post-treatment (Randomization through Final Visit [Week 6]) ] [ Designated as safety issue: No ]
    Pain relief was defined as at least a 2-grade reduction in pain intensity on a 5-grade scale in participants who had not used headache rescue medication before assessment. A pain intensity score of 5 was assigned for all subsequent assessments if a participant took rescue medication (a single oral dose for the treatment of migraine pain or associated symptoms). The 5-grade scale is a participant's self-rating scale to assess the pain intensity of a migraine with the following scores: 1 = none, 2 = mild, 3 = mild to moderate, 4 = moderate to severe, and 5 = severe.


Secondary Outcome Measures:
  • Percentage of Participants Who Reported Pain Relief at 30, 60, 120, and 240 Minutes Post-Treatment [ Time Frame: 30, 60, 120, and 240 minutes post-treatment (Randomization through Final Visit [Week 6]) ] [ Designated as safety issue: No ]
    Pain relief was defined as at least a 2-grade reduction in pain intensity on a 5-grade scale in participants who had not used headache rescue medication before assessment. A pain intensity score of 5 was assigned for all subsequent assessments if a participant took rescue medication (a single oral dose for the treatment of migraine pain or associated symptoms). The 5-grade scale is a participant's self-rating scale to assess the pain intensity of a migraine with the following scores: 1 = none, 2 = mild, 3 = mild to moderate, 4 = moderate to severe, and 5 = severe.

  • Percentage of Participants Who Were Pain Free at 30, 60, 120, and 240 Minutes Post-Treatment [ Time Frame: 30, 60, 120, and 240 minutes post-treatment (Randomization through Final Visit [Week 6]) ] [ Designated as safety issue: No ]
    Pain free was defined as a post-treatment pain intensity score of 1 on a 5-grade scale in participants who had not used headache rescue medication before assessment. A pain intensity score of 5 was assigned for all subsequent assessments if a participant took a rescue medication. The 5-grade scale is a participant's self-rating scale to assess the pain intensity of a migraine with the following scores: 1 = none, 2 =mild, 3=mild to moderate, 4=moderate to severe, and 5=severe.

  • Percentage of Participants Who Were Photophobia Free at 30, 60, 120, and 240 Minutes Post-Treatment [ Time Frame: 30, 60, 120, and 240 minutes post-treatment (Randomization through Final Visit [Week 6]) ] [ Designated as safety issue: No ]
    Photophobia (sensitivity to light) is one of the associated symptoms of a migraine. A participant was assessed as photophobia free when the symptom was recorded as "absent" at each time point in his or her patient diary. Photophobia was recorded as "present" for all subsequent assessments if a participant took rescue medication.

  • Percentage of Participants Who Were Phonophobia Free at 30, 60, 120, and 240 Minutes Post-Treatment [ Time Frame: 30, 60, 120, and 240 minutes post-treatment (Randomization through Final Visit [Week 6]) ] [ Designated as safety issue: No ]
    Phonophobia (sensitivity to sound) is one of the associated symptoms of a migraine. A participant was assessed as phonophobia free when the symptom was recorded as "absent" at each time point in his or her patient diary. Phonophobia was recorded as "present" for all subsequent assessments if a participant took rescue medication.

  • Percentage of Participants Who Were Nausea Free at 30, 60, 120, and 240 Minutes Post-Treatment [ Time Frame: 30, 60, 120, and 240 minutes post-treatment (Randomization through Final Visit [Week 6]) ] [ Designated as safety issue: No ]
    Nausea is one of the associated symptoms of a migraine. A participant was assessed as nausea free when the symptom was recorded as "absent" at each time point in his or her patient diary. Nausea was recorded as "present" for all subsequent assessments if a participant took rescue medication.

  • Percentage of Participants Who Were Free of Vomiting at 30, 60, 120, and 240 Minutes Post-Treatment [ Time Frame: 30, 60, 120, and 240 minutes post-treatment (Randomization through Final Visit [Week 6]) ] [ Designated as safety issue: No ]
    Vomiting is one of the associated symptoms of a migraine. A participant was assessed as being free of vomiting when the symptom was recorded as "absent" at each time point in his or her patient diary. Vomiting was recorded as "present" for all subsequent assessments if a participant took a rescue medication.

  • Percentage of Participants Who Used Rescue Medication Between the Time of Dosing and 240 Minutes Post-Treatment [ Time Frame: within 240 minutes post-treatment (Randomization through Final Visit [Week 6]) ] [ Designated as safety issue: No ]
    Rescue medication included one of the following: a single oral dose of a nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen, not to exceed the maximum recommended single dose; and anti-emetics (a drug to prevent vomiting).


Enrollment: 178
Study Start Date: September 2009
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Sumatriptan 25 mg Drug: Sumatriptan 25 mg
One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
Active Comparator: Sumatriptan 50 mg Drug: Sumatriptan 50 mg
Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
Placebo Comparator: Placebo Drug: Placebo
Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.

  Eligibility

Ages Eligible for Study:   10 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is >10 years of age and <17 years of age at the informed consent and the Randomization Visit.
  • Subject has migraine with or without aura (ICHD-II criteria, 1.1 or 1.2.1). A minimum of a six month history of migraine prior to entry into the study is required.
  • Subject has a history of at least two, but no more than eight, attacks per month for the two months prior to entry into the study.
  • All migraine attacks associated with 3 or more pain on a 5-grade scale should last a minimum of three hours for the two months prior to entry into the study.
  • Subject has shown nonresponse to at least one NSAIDs or acetaminophen for the two months prior to entry into the study.
  • Subject is able to distinguish migraine from other headaches (e.g., tension-type headache).
  • Subject is able to read, comprehend, and complete subject diaries.
  • Males or female subjects. Female subjects are eligible for participation in the study if they are one of the following
  • Females of non-childbearing potential (i.e., physiologically incapable of becoming pregnant or have undergone female sterilization)
  • Females of childbearing potential, and who have a negative pregnancy test at the Screening Visit, and agree to use one of the following GlaxoSmithKline (GSK)-specified highly effective methods for avoiding pregnancy:
  • Abstinence
  • Oral Contraceptive, either combined or progestogen alone
  • Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject)
  • Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository)
  • Subject's parent or legal guardian is willing and able to provide informed consent prior to subject entry into the study.
  • Subject is willing and able to provide informed assent prior to entry into the study.
  • Subjects considered for enrolment must have a QTc (either QTc B (Bazett's correction) or QTc F (Fridericia's correction)) <450msec at the Screening Visit, with the exception of subjects with bundle branch block (for whom either QTc B or QTc F must be <480msec).

Note: For the purposes of these criteria, QTc B is defined as (QT interval msec) / (square root of RR interval seconds); and QTc F is defined as (QT interval msec) / (cube root of RR interval seconds).)

  • Liver function test at the Screening Visit: AST and ALT <2xULN; alkaline phosphatase and total bilirubin <1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)

Exclusion Criteria:

  • Subject is < 30 kg.
  • Subject has 15 or more headache days per month in total (migraine, probable migraine, or tension-type). Subject has retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), hemiplegic (ICHD-II 1.2.4 or 1.2.5), or Ophthalmoplegic migraine (ICHD-II 13.17). Subject has secondary headaches.
  • Subject has a history of cerebrovascular disease or ischemic cerebrovascular disease.
  • Subject has a history of myocardial infarction.
  • Subject has uncontrolled hypertension.
  • Subject has symptoms or signs of ischemic cardiac syndromes.
  • Subject has variant angina.
  • Subject has evidence of a peripheral vascular syndrome.
  • Subject has evidence or history of epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control.
  • Subject has a history of impaired hepatic or renal function that, in the investigator (or subinvestigator)'s opinion, contraindicates participation in this study. Subject has unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice). Subject has cirrhosis. Subject has known biliary abnormalities (with the exception of Gilberts's syndrome or asymptomatic gallstones).
  • Subject has hypersensitivity, allergy, intolerance, or contraindication to the use of any triptan (including all sumatriptan preparations) or sulfonamide compounds.
  • Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized (i.e., change of dose within the past 2 months) for either chronic or intermittent migraine prophylaxis.
  • Subject has taken, or plans to take, a monoamine oxidase inhibitor (MAOI) anytime within the two weeks prior to entry into the study.
  • Subject has evidence of psychotropic, alcohol, or substance abuse within the last year.
  • Subject has participated in any investigational drug trial within the previous 3 months or plans to participate in another study at any time during this study.
  • Subject has any concurrent medical or psychiatric condition which, in the investigator (or subinvestigator)'s judgment, contraindicates participation in this clinical trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00963937

Locations
Japan
GSK Investigational Site
Aichi, Japan, 467-8602
GSK Investigational Site
Aichi, Japan, 450-0002
GSK Investigational Site
Hokkaido, Japan, 060-0004
GSK Investigational Site
Hokkaido, Japan, 060-8570
GSK Investigational Site
Hyogo, Japan, 658-0064
GSK Investigational Site
Hyogo, Japan, 663-8204
GSK Investigational Site
Kagoshima, Japan, 892-0844
GSK Investigational Site
Kanagawa, Japan, 215-0021
GSK Investigational Site
Kanagawa, Japan, 252-0375
GSK Investigational Site
Kanagawa, Japan, 221-0835
GSK Investigational Site
Kyoto, Japan, 600-8811
GSK Investigational Site
Osaka, Japan, 560-0012
GSK Investigational Site
Saitama, Japan, 336-8522
GSK Investigational Site
Tokyo, Japan, 101-0021
GSK Investigational Site
Tokyo, Japan, 132-0024
GSK Investigational Site
Tokyo, Japan, 105-7103
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT00963937     History of Changes
Other Study ID Numbers: 111035
Study First Received: August 20, 2009
Results First Received: July 28, 2011
Last Updated: July 28, 2011
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by GlaxoSmithKline:
adolescent
sumatriptan
children
migraine

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Sumatriptan
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 23, 2014